Career Summary

• Since 2014      Affiliated Professor, University of the Free State, Bloemfontein, South Africa
• Since 2020      Head of Clinical Data Science and Analytics, Hexal/Sandoz, Holzkirchen, Germany
• 2015 - 2020     Head of Statistics and Programming, medac, Hamburg, Germany
• 2013 - 2015     Principal Statistician, Leicester Clinical Trials Unit, University of Leicester, UK
• 2011 - 2012     Head of Statistics and Modelling Group, Diabetes Trials Unit, University of Oxford, UK
• 2007 - 2011     Team leader Phase I/IIa biostatistics, Boehringer Ingelheim Pharma, Biberach, Germany
• 2002 - 2007     Biostatistician, Boehringer Ingelheim Pharma, Biberach, Germany
• 2000 - 2002     Actuary (Non-life reinsurance), GE Frankona Re, München, Germany 

• Associate Fellowship of the Higher Education Academy, UK, 2013
• Certificate MQ-1 “Teaching for Medical Students”, University of Ulm, 2011
• PhD in Pharmacometrics, Martin-Luther-University Halle-Wittenberg, 2001
• Diploma in mathematics (MSc equivalent) at the Martin-Luther-University Halle-Wittenberg (Germany), 1996

Publications

• Author of >35 papers in peer-reviewed journals, >10 of them as first or last author
• More than 70 abstracts to clinical and statistical conferences
• More than 25 invited presentations as international and national conferences

Statistical methodology

1. Ring A, Morris TBS, Koytchev R, Hohl K, Schall R. (2014) Indirect bioequivalence assessment using network meta-analyses. Eur J Clin Pharmacol. Accepted.
2. Glomb P, Ring A (2012) Delayed effects in the „exposure-response“ analysis of clinical QTc-Studies. J Biopharm Stat. 22(2):387-400.
3. Schall R, Ring A (2011) Mixed model for data from thorough QT studies. Part 1: Assessment of marginal QT prolongation. Pharm Stat. 10(3):265-76. doi: 10.1002/pst.463.
4. Schall R, Endrenyi, L. Ring, A. (2010) Residuals and outliers in replicate design crossover studies. J Biopharm Stat. 20(4):835-49.
5. Ring A, Walter B, Larbalestier A, Chanter D. (2010) An efficient crossover design for thorough QT studies. GMS Med Inform Biom Epidemiol. 6(1):Doc05.
6. Schall R, Ring, A. (2010) Statistical Characterization of QT Prolongation. J Biopharm Stat  20(3); 543 – 562.
7. Ring A (2010) Statistical models for heart rate correction of the QT interval. Statist Med 29 (7-8), 786–796.
8. Ring A, Tothfalusi L, Endrenyi L, Weiss M. (2000) Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. Pharm Res. 17(5):583-8.

Teaching statistics and Evidence Based Medicine (in German)

1. Ring A (2014) Ein (statistischer) Werkzeugkastenfür eine Vorlesung „Klinische Studien“ für Nicht-Statistiker. In: Rauch G, Muche R, Vontheim R. Zeig mir Biostatistik! Ideen und Material für einen guten Biometrie-Unterricht. Spinger-Lehrbuch.
2. Ring A (2012) Tennis – Ein Bleistiftspiel mit künstlicher Intelligenz (English: „Tennis – A pencil game with artificial intelligence“).  Die Wurzel, Jena, p. 183-188.
3. Ring A, Ring C, Lutz D. (2010) Einsatz der Zeitschrift “Hygiene und Medizin” in der Weiterbildung zur Hygienefachkraft. (en: Use of the journal „Hygiene und Medizin“ for the training to the degree of “infection control nurse”). Hyg Med. 35 (11): 412-420.
4. Häggström O. (2006) Streifzüge durch die Wahrscheinlichkeitstheorie. Springer-Lehrbuch. Translation from Swedish: Ring A.

1. Schaller S, Martins FS, Balazki P, Böhm S, Baumgart J, Hilger RA, Beelen DW, Hemmelmann C, Ring A. (2022) Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach. Br J Clin Pharmacol. 88(4):1722-1734. doi: 10.1111/bcp.15081 
2. Ring A, Brand T, Macha S, Breithaupt-Groegler K,Walter B, Broedl U. (2013) The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc. Diabetol. 12:70. doi:10.1186/1475-2840-12-70.
3. Ring A, Rathgen K, Feifel U, Stangier, Reilly, P, Friedman J. (2013) Dabigatran does not prolong the QT interval with supratherapeutic exposure – a thorough QT study. Clin Drug Invest. 33(5):333-42. doi: 10.1007/s40261-013-0058-0.2
4. Ring A, Port A, Graefe-Mody EU, Revollo I, Iovino M, Dugi KA. (2011) The DPP-4 inhibitor Linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol. 72(1):39-50. doi: 10.1111/j.1365-2125.2011.03931.x.

Clinical Trials - Recent publications as statistical author

1. Krause J, Agarwal S, Bodicoat D, Ring A, Shepherd D, Rogers S, Wensing M, Baker R. (2014) Evaluation of a tailored intervention to improve management of overweight and obesity in primary care; study protocol of a cluster randomised controlled trial. Trials, 15:82.doi:10.1186/1745-6215-15-82.
2. Metzmann K, Schnell D, Jungnik A, Ring A, Theodor R, Hohl K, Meinicke T, Friedrich C. (2014) Food and tablet-dissolution characteristics do not affect the bioavailability of linagliptin fixed dose combination with metformin: evidence from two randomized trials. Int J Clin Pharmacol Ther Accepted.
3. Buschke S, Ring A, Friedrich C, Metzmann K, Meinicke T. (2014) Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets. Int J Clin Pharmacol Ther Accepted.
4. Friedrich C, Jungnik A, Retlich S, Ring A, Meinicke, T. (2014) Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: Pharmacokinetics and pharmacodynamics in an open-label crossover trial. Drug Research. doi: 10.1055/s-0033-1357144.
5. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman, RR. (2013) Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.Am Heart J. 166(6):983-989.e7 Doi:/10.1016/j.ahj.2013.09.003
6. Bethel MA, Price H, Sourij H, White S, Coleman R, Ring A, Kennedy I, Tucker L, Holman R. (2013) Evaluation of a Self-administered Oral Glucose Tolerance Test. Diabetes Care. 36(6): 1483-1488,doi: 10.2337/dc12-0643
7. Rauch T, Graefe-Mody U, Ring A, Deacon CF, Holst JJ, Woerle HJ, Dugi KA and Heise T. (2012) Linagliptin increases incretin levels, lowers glucagon, and rapidly improves glycaemic control in patients with Type 2 diabetes. Diabetes Ther. 3(1):10. doi: 10.1007/s13300-012-0010-y.
8. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ. (2011) Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 13(10):939-46. doi: 10.1111/j.1463-1326.2011.01458.x.
9. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. (2011)The novel, potent and selective DPP-4 inhibitor BI 1356 significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 13(6): 542-50.
10. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA (2010). Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 27(12):1409-19. doi: 10.1111/j.1464-5491.2010.03131.x.
11. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA (2009) Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 25(8):1963-72.
12. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA.(2009) Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 11(8):786-94.
13. Huettner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA (2008) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 48 (10), 1171 – 1178.
14. Huang F, Koenen-Bergmann M, MacGregor T, Ring A, Hattox S, Robinson R (2008). Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrobial agents and chemotherapy, 52 (12): 4300–4307.
15. Klueglich M, Ring A, Scheuerer S, Trommeshauser D, Schuijt C, Liepold B, Berndl G. (2005). Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol. 45(9):1055-61.

1.   Repeated measurement analysis with time-variant covariates
               Focus on “Thorough QT studies” in crossover design (with Robert Schall)

2.  Indirect comparisons of treatments using individual patient data
               Improved methodology for indirect comparisons of bioequivalence trials  (with Robert Schall)

3.   CONSORT check list for clinical pharmacology trials
               Pilot phase completed end of 2012, published at ISCB 2013

4.   Teaching EBM
               Development of modules for clinical trials and EBM for non-statisticians

5.  Biomarker analysis
              Personalisation of diabetes status using HbA1c and other biomarkers

Actuarial Science

1. Reserve estimation in volatile non-life insurance
               Improvements of chain-ladder methods using external information

Probability theory

1.  Lumpability of Markow chains using symmetries
              Symmetries in transition matrices and state vectors

2. Artificial intelligence
              Analysis of strategic games using computer algorithms